Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Actuate Therapeutics Inc.
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
Children's Oncology Group
Essen Biotech
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Southern California
Massive Bio, Inc.
UNC Lineberger Comprehensive Cancer Center
Incyte Corporation
University of Wisconsin, Madison
AVM Biotechnology Inc
Barbara Ann Karmanos Cancer Institute
Miltenyi Biomedicine GmbH
Cedars-Sinai Medical Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Taproot Health
National Cancer Institute (NCI)
University of Virginia
Norwegian University of Science and Technology
Assistance Publique - Hôpitaux de Paris
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
AbbVie
M.D. Anderson Cancer Center
Bristol-Myers Squibb
National Institute of Allergy and Infectious Diseases (NIAID)
Rutgers, The State University of New Jersey
Northwestern University
Roswell Park Cancer Institute
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Jonsson Comprehensive Cancer Center
Case Comprehensive Cancer Center
Celgene
Vanderbilt-Ingram Cancer Center
City of Hope Medical Center
University of Texas Southwestern Medical Center